investor
Incyte’s oral HS drug hits study goals, but fails to excite investors
povorcitinib, JAK1 inhibitor, hidradenitis suppurativa, Phase 3 trials, efficacy, investor reaction, regulatory submission
AstraZeneca Shares Rise as China Investigation Impact Appears Limited
AstraZeneca, China investigation, share price, financial performance, import taxes, investor confidence
Biotech IPO Market Expected to Rebound in 2025 with Increased Investor Optimism
Biotech IPOs, 2025 Outlook, Investor Optimism, Therapeutic Innovation, Strategic Differentiation
Novo Nordisk’s CagriSema Falls Short of Weight Loss Expectations, Highlighting High Investor Expectations
CagriSema, Novo Nordisk, Weight Loss Drugs, REDEFINE 1 Trial, Obesity Treatment, Investor Expectations
Applied Therapeutics Undergoes Leadership Change Amid FDA Rejection and Investor Lawsuit
Applied Therapeutics, FDA rejection, investor lawsuit, leadership change, John H. Johnson, Les Funtleyder, Shoshana Shendelman
UnitedHealthcare CEO Brian Thompson Fatally Shot in Targeted Attack Outside New York City Hotel
UnitedHealthcare, CEO Brian Thompson, targeted killing, New York City, hotel shooting, investor meeting
NewAmsterdam’s CETP Inhibitor Obicetrapib Achieves Phase 3 Success but Fails to Meet Investor Expectations
NewAmsterdam Pharma, CETP inhibitors, obicetrapib, cholesterol-lowering drugs, Phase 3 trials, investor expectations, LDL cholesterol reduction
Amgen Faces Investor Lawsuit Over $10.7 Billion Tax Liability
Amgen, investor lawsuit, tax liability, $10.7 billion, legal challenge
Aligos Therapeutics Reports Positive Phase IIa Results for MASH Treatment, Despite Investor Skepticism
Aligos Therapeutics, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase IIa trial, ALG-055009, Liver fat reduction, Investor skepticism, Placebo effect
Aligos Therapeutics’ HERALD Study Shows Promising MASH Treatment Results, Yet Fails to Impress Investors
Aligos Therapeutics, HERALD study, MASH treatment, ALG-055009, liver fat reduction, Phase 2a results, investor reaction.